title: Moving forward - essential questions for the next 10 years.
abstract: The future is bright for migraine sufferers. For acute treatment, CGRP antagonists and combination products will provide more complete, longer lasting, and safer relief. "Designer drugs" for migraine prevention will be identified based on their ability to block cortical spreading depression and will improve migraine treatment. Genetic and environmental risk factors that promote migraine progression will be identified and preventing progression will become a standard goal in treatment. Some of the devices intended to treat migraine will be approved and will provide important options for sufferers seeking to avoid drugs. Clinical trials that evaluate behavioral and pharmacologic interventions and their impact on patient centered outcomes will emerge. The emergence of novel treatments, when coupled with strategies for individualizing and optimizing treatment while maximizing adherence, will result in ever improving patient outcomes.
authors.affiliation: Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Lipton
authors.forename: Fred D
authors.initials: FD
authors.lastname: Sheftell
mesh_terms: D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D018450:Disease Progression; D015195:Drug Design; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D015740:Calcitonin Gene-Related Peptide